Research · the published record
The CJC-1295 research record: mechanism, human pharmacokinetics, and the class it belongs to
What the peer-reviewed literature on CJC-1295 measured — receptor signaling, the human GH and IGF-1 kinetics, and the analytical work that identified the compound in seized products.
A Literature Review of CJC-1295
A literature review of CJC-1295 returns a compact, coherent body of work. The foundational pharmacokinetics come from two human studies and one rat bioconjugation study; the rest is animal, proteomic, and analytical work, plus recent reviews of the broader GHRH-analog class.
The central human finding: single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean growth hormone for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days; after multiple doses, IGF-1 stayed above baseline up to 28 days, with an estimated half-life of 5.8 to 8.1 days [1]. That single paper carries most of the weight in any honest CJC-1295 summary.
The rat work explains the mechanism behind the duration. A series of hGRF(1-29) analogs bearing a maleimidopropionyl-lysine handle were screened; the lead, CJC-1295, combined four protease-resistant substitutions with covalent bonding to serum albumin and showed a 4-fold increase in growth-hormone area-under-the-curve over two hours versus unconjugated hGRF(1-29), with peptide detectable in plasma beyond 72 hours [2].
How CJC-1295 Stimulates Growth Hormone
CJC-1295 binds the growth-hormone-releasing hormone receptor, a class B G-protein-coupled receptor on pituitary somatotrophs. Receptor activation drives Gs/adenylate cyclase/cAMP/PKA signaling and CREB-mediated growth-hormone gene transcription; the released growth hormone then acts on hepatic GH receptors through JAK2/STAT5 to raise IGF-1 [1].
Four substitutions on the hGRF(1-29) backbone — D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27 — stabilize the helix and block dipeptidylpeptidase-IV cleavage, deamidation, and oxidation. In the DAC variant, a C-terminal lysine carries a maleimidopropionyl linker that undergoes Michael addition with the free thiol on Cys34 of serum albumin, forming a covalent peptide-albumin conjugate [2]. This bioconjugation is the structural reason the long-acting form persists for days.
The animal evidence that the mechanism translates into function comes from GHRH-knockout mice. Two micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective, and treatment raised pituitary growth-hormone mRNA [4]. A once-daily schedule of the long-acting analog was sufficient to restore GH-axis-dependent growth in an animal that otherwise could not produce it.
What the Research Reports on CJC-1295
Framed as measured outcomes rather than claimed benefits, what the research reports on CJC-1295 is consistent across the human studies: a sustained, dose-dependent rise in growth hormone and IGF-1 with preserved pulsatility.
In healthy men, a single 60 or 90 microgram-per-kilogram dose raised basal growth hormone about 7.5-fold and IGF-1 about 45 percent one week later, without altering the natural pulse pattern [3]. A proteomic study in 11 healthy young men found that CJC-1295 reproducibly shifted the serum proteome — decreasing apolipoprotein A1 and a transthyretin isoform, increasing a C-terminal albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal tracked linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5].
These are biomarker outcomes. The studies measured hormone levels and protein signatures, not body composition, performance, or longevity endpoints. Outcome claims of the kind that circulate in community discussion are not what these papers tested, and this digest does not extend the data past what it measured.
CJC-1295 and Ipamorelin: The Two-Receptor Rationale
The rationale for pairing CJC-1295 with ipamorelin is mechanistic and specific. CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a selective growth-hormone-releasing peptide acting on the ghrelin/growth-hormone-secretagogue receptor. The two engage different receptors on the same somatotroph, and co-administration of a GHRH with a GHRP produces supra-additive growth-hormone release in mechanistic studies [1].
That is the entire evidentiary basis for the combination at present. There are no controlled human trials of the CJC-1295 and ipamorelin pairing for body-composition, performance, or anti-aging endpoints. The synergy is documented at the level of acute growth-hormone release through two receptors; the outcomes people attribute to the stack are not established by trial data.
Ipamorelin's appeal in this pairing is its selectivity — it was characterized as the first highly selective growth-hormone secretagogue, releasing growth hormone with minimal effect on ACTH, cortisol, or prolactin. The combination is studied because the receptors are distinct, not because a controlled outcome trial validated it.
CJC-1295 Within the GHRH-Analog Class
Situating CJC-1295 within the GHRH-analog class is the most useful way to read its evidence. The class includes sermorelin and the approved drug tesamorelin, and current reviews treat them together. A 2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its synthetic analogues — receptor signaling, the rationale for long-acting analog design, and their therapeutic and investigational landscapes [6]. A 2024 review traced the development of GHRH analogs across cancer, regenerative medicine, and metabolic disease, providing current context for where unapproved analogs like CJC-1295 sit relative to approved agents [7].
Tesamorelin is the closest approved comparator, indicated for HIV-associated lipodystrophy, and a 2026 analysis reported its body-composition, hepatic-fat, metabolic, and safety outcomes — the approved-analog evidence base that serves as the benchmark CJC-1295 has not generated for itself [8]. A 2026 review of approved and unapproved peptide therapies for musculoskeletal conditions addressed the same evidence gap directly [9].
The class framing is what keeps CJC-1295 honest. An approved GHRH analog has defined indications and trial data; CJC-1295 shares the receptor and the design logic but not the clinical record.
What does the published human research on CJC-1295 actually show?
Published human data are limited to early pharmacokinetic studies. Single subcutaneous doses of 30-60 micrograms per kilogram raised mean growth hormone 2- to 10-fold for about six days and IGF-1 1.5- to 3-fold for nine to eleven days [1], and 60-90 micrograms per kilogram raised basal GH about 7.5-fold with pulsatility preserved [3]. There are no large efficacy or long-term safety trials in healthy adults.
Is CJC-1295 studied for anti-aging or longevity?
The cited rationale is somatopause, the age-related decline of the GH/IGF-1 axis, and CJC-1295 reproducibly elevates GH and IGF-1 [5]. But direct peer-reviewed evidence for anti-aging benefit in healthy adults is thin and short-term; recent GHRH-analog reviews discuss the class in regenerative and metabolic contexts rather than validated longevity outcomes [6].
Does CJC-1295 and ipamorelin work?
Each agent raises growth hormone through a different receptor, and co-administration of a GHRH with a GHRP produces supra-additive growth-hormone release in mechanistic studies [1]. But there are no controlled human trials of the CJC-1295 and ipamorelin combination for body-composition or anti-aging endpoints; the evidence is mechanistic, not outcome-based.
What is CJC-1295 ipamorelin?
It refers to combining CJC-1295, a GHRH analog, with ipamorelin, the first highly selective growth-hormone secretagogue, which releases growth hormone with minimal ACTH, cortisol, or prolactin effect. The two act on separate receptors, which is the basis for studying them together [1].
What to expect when taking CJC-1295?
The documented physiological response in studies is elevated growth hormone and IGF-1 over days, with GH pulsatility preserved [3]. Beyond these biomarker changes, outcome expectations such as body composition, performance, or anti-aging are not validated by controlled human trials.